STOCK TITAN

Rhythm Pharmaceuticals (RYTM) CAO exercises RSUs, withholds shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Rhythm Pharmaceuticals Corporate Controller and Chief Accounting Officer Christopher Paul German reported routine equity compensation activity. On March 1, 2026, he exercised 1,162 restricted stock units, receiving the same number of common shares at $0.00 per share. Of these, 342 common shares were automatically withheld at $94.94 per share to cover tax obligations, rather than sold on the open market. After these transactions, he directly owned 4,253 shares of common stock. The underlying restricted stock units vest in four equal 25% installments on March 20, 2024, March 20, 2025, March 1, 2026, and March 1, 2027, contingent on continued service.

Positive

  • None.

Negative

  • None.
Insider German Christopher Paul
Role Corporate Controller & CAO
Type Security Shares Price Value
Exercise Restricted Stock Units 1,162 $0.00 --
Exercise Common Stock 1,162 $0.00 --
Tax Withholding Common Stock 342 $94.94 $32K
Holdings After Transaction: Restricted Stock Units — 1,162 shares (Direct); Common Stock — 4,595 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. The restricted stock units vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 1, 2026 and March 1, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
German Christopher Paul

(Last) (First) (Middle)
222 BERKELEY STREET, 12TH FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Corporate Controller & CAO
3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/01/2026 M 1,162 A (1) 4,595 D
Common Stock 03/01/2026 F(2) 342 D $94.94 4,253 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 03/01/2026 M 1,162 (3) (3) Common Stock 1,162 $0 1,162 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.
3. The restricted stock units vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 1, 2026 and March 1, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.
/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did RYTM executive Christopher Paul German report?

Christopher Paul German exercised 1,162 restricted stock units into common stock and had 342 of those shares withheld to pay taxes. These transactions reflect routine equity award vesting and tax withholding rather than open-market buying or selling activity.

How many Rhythm Pharmaceuticals (RYTM) shares does the CAO own after this Form 4?

Following these transactions, Christopher Paul German directly owns 4,253 shares of Rhythm Pharmaceuticals common stock. This balance reflects the RSU conversion into 1,162 shares and the withholding of 342 shares to satisfy tax liabilities associated with the vesting event.

Were any Rhythm Pharmaceuticals (RYTM) shares sold on the open market in this filing?

No open-market sales are reported. The 342 Rhythm Pharmaceuticals shares labeled as a disposition were withheld by the company to cover tax obligations arising from RSU vesting, a common administrative mechanism rather than a discretionary sale by the executive.

What is the vesting schedule of the RSUs reported for RYTM’s CAO?

The restricted stock units vest in four equal 25% installments on March 20, 2024, March 20, 2025, March 1, 2026, and March 1, 2027. Each vesting tranche requires Christopher Paul German’s continued service through the respective vesting date.

What do the Form 4 transaction codes M and F mean for RYTM?

Code M indicates the exercise or conversion of a derivative security, here RSUs converting into common stock. Code F represents shares withheld to pay exercise price or taxes, showing tax-withholding dispositions rather than typical market sales by the insider.

Does this Rhythm Pharmaceuticals (RYTM) Form 4 indicate bullish or bearish insider sentiment?

The filing mainly reflects routine RSU vesting and related tax withholding, not discretionary buying or selling. Such administrative equity compensation events generally provide limited insight into the insider’s sentiment toward Rhythm Pharmaceuticals’ future performance or valuation.